【US Stock Movements】Grail surged on October 9: Regulatory support, Galleri data, and growth in testing
Bitget异动解读2026/10/09 14:05Grail October 9th Surge Interpretation
Keywords: Regulatory Support, Galleri Data, Detection Growth
1. On September 23rd, the FDA Medical Devices Advisory Committee voted 10 to 0 on the safety of Galleri, 7 to 2 that the benefits outweigh the risks, and 6 to 4 on its effectiveness, providing regulatory progress for subsequent PMA review.
2. From October 6th to 8th, GRAIL presented six sets of data at EDCC regarding Galleri's clinical performance, health equity, and real-world applications, including detection of more than 200 types of cancer and determination of cancer signal sources.
3. As of June 30th, Galleri's testing volume in the first half of the year increased by 42% year-on-year to over 117,000 tests; the company mainly focuses on early detection of multiple cancer types, with Galleri as a commercialized blood screening product.
(Disclaimer: This content is summarized from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. stocks move | Moderna (MRNA.US) rises 7% after being included in the Nasdaq 100 Index
According to information from Zhihui Finance APP, on Friday, Moderna (MRNA.US) surged as much as 10% during trading, reaching its highest share price since December 2022. As of press time, the gain narrowed to 7%, with the stock trading at $210.95. On the news front, on October 9, Moderna was officially included in the Nasdaq 100 index, replacing Warner Bros Discovery. After its inclusion, some broad-based institutions that previously did not allocate to biotech will now passively hold the stock, while active institutions will add the company to their watch lists, increasing attention on the individual stock.
